![Mark Frohlich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Frohlich
Directeur/Membre du Conseil chez
RIGEL PHARMACEUTICALS, INC.
Fortune : 273 840 $ au 30/06/2026
Profil
Mark J.
Frohlich is currently Chief Executive Officer & Director at Indapta Therapeutics, Inc. since 2022.
He serves as Director at BioEclipse Therapeutics, Inc. since 2019 and at Neuvogen, Inc. since 2021.
He is also an Independent Director at Rigel Pharmaceuticals, Inc. starting in 2025.
Formerly, Dr. Frohlich was Vice President & Medical Director at Xcyte Therapies, Inc. from 2001 to 2005.
He was Chief Medical Officer & EVP-Research & Development at Dendreon Corp.
from 2012 to 2014.
He held the position of Assistant Professor at The University of California, San Francisco from 1998 to 2001.
He worked as Executive Vice President-Portfolio Strategy at Juno Therapeutics, Inc. from 2016 to 2017.
Dr. Frohlich completed undergraduate studies at Yale University in 1984 and earned a doctorate from Harvard Medical School in 1990.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/05/2026 | 7 000 ( 0,04 % ) | 273 840 $ | 30/06/2026 |
Postes actifs de Mark Frohlich
| Sociétés | Poste | Début |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 06/03/2025 |
BioEclipse Therapeutics, Inc.
 BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops curative immune-oncology therapeutics | Directeur/Membre du Conseil | 24/06/2019 |
Neuvogen, Inc.
 Neuvogen, Inc. BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Directeur/Membre du Conseil | 23/08/2021 |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Directeur Général | 10/02/2022 |
Anciens postes connus de Mark Frohlich
| Sociétés | Poste | Fin |
|---|---|---|
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/09/2017 |
| DENDREON CORPORATION | Directeur Technique/Scientifique/R&D | 01/02/2014 |
Xcyte Therapies, Inc.
 Xcyte Therapies, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products | Directeur Technique/Scientifique/R&D | 01/07/2005 |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2001 |
Formation de Mark Frohlich
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
93
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Rigel Pharmaceuticals, Inc.
 Rigel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which discovers, develops and provides novel small-molecule drugs | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
Xcyte Therapies, Inc.
Xcyte Therapies, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops curative immune-oncology therapeutics | Health Technology |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Develops proprietary, off-the-shelf, allogeneic natural killer cell therapy to treat cancer | Health Technology |
Neuvogen, Inc.
Neuvogen, Inc. BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
